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Introduction . Synchronous metastases of gastric cancer to the liver occur in 3–14% of patients with this cancer, and 
metachronous lesions in 37% of patients after radical gastrectomy. Liver resections due to metastases of gastric carcinomas 
represent only 5–9% of resections due to metastases other than colorectal cancer. Until recently, patients with gastric 
carcinoma metastases to the liver were classified in the IV stage of cancer and the therapy was limited to chemotherapy 
or palliative treatment only.  
Material and methods . The paper presents a current review of literature and the authors’ own experience with liver 
resection due to gastric cancer metastases into this organ. During 34 months, 488 patients with liver metastases were 
treated in the Department of General, Transplant and Liver Surgery, of the Medical University of Warsaw, in whom 426 
surgical procedures were performed (87.3%). The types of surgical procedures are as follows: minor liver resections in 204 
patients (47.9%), hemihepatectomies in 102 patients (23.9%), thermoablations in 86 patients (20.2%) and laparotomies in 
34 patients (8.0%). Among patients treated for liver metastases there were 4 patients with metastases from gastric cancer 
(0.8%), which constituted 1% of patients operated on, but 6.8% of patients with liver metastases from organs other than 
colorectal cancer. The postoperative course and direct results in all patients operated because of gastric cancer metastases 
into the liver were very good.
Conclusions . In some patients (single metachronous metastasis, no extrahepatic lesions, no peritoneal lesions, with 
subsequent chemotherapy) liver resection due to metastases from gastric cancer provides a chance for a longer survival. 
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Introduction
Synchronous metastases of gastric cancer to the liver occur in 
3–14% of patients [1, 2], and metachronous lesions – in 37% of 
patients after radical gastrectomy [3]. These percentages are 
similar to the group of patients with colorectal cancer meta-
stases to the liver. Liver resections due to metastases of gastric 
carcinomas, however, constitute only 5–9% of resections due 
to metastases other than colorectal cancer [4–7].
This is due, among other things, to the fact that until recen-
tly, patients with metastases of gastric cancer into the liver were 
disqualified from surgical treatment and offered chemotherapy 
only. Such an approach was based on the Japanese classifi-
cation of gastric cancer, indicating that patients in this period 
of cancer development belong to the IV stage of the disease, 
therefore the therapy should be limited to chemotherapy or 
palliative treatment [8]. 
One of the factors that influence the negative decision 
to remove metastases of gastric cancer from the liver is the 
coexistence of these metastases with metastases to other 
organs and structures – to the peritoneum or lymph nodes 
[6]. Moreover, single metastases of gastric cancer into the liver 
occur in only 0.5% of patients [9].
In 2008, a randomized Japanese and Korean study was 
published, which shed new light on the treatment of gastric 
2cancer patients with single stage factor , i.e. a liver metastasis 
[10]. Since then, the approach of surgeons has been changing 
and they more and more often remove gastric cancer meta-
stases from the liver [11–14]. 
Material
At the Department of General, Transplant and Liver Surgery 
of the Medical University of Warsaw, 488 people were treated 
within 34 months due to liver tumor metastases. In the whole 
group, patients with gastric cancer metastases constituted 
0.8% (4 patients) (Tab. I). After analyzing the number of patients 
with liver metastases only from organs other than colorectal 
cancer, it turned out that the percentage of patients with 
metastases of gastric cancer was already 6.8% (Tab. II). 
Out of all 488 patients with liver cancer metastases, 426 
patients (87.3%) received surgery (Tab. III). 
Four patients were operated on because of gastric cancer 
metastases. In three of them there were metachronous metasta-
ses, and in one – synchronous metastases. In one patient meta-
chronous liver metastases occurred 27 years after gastrectomy. 
Polycyclic lesions were located at the border of segments II, III, 
IVA and IVB (Fig. 1). Metastatic lesions also appeared in the lymph 
nodes over the proper hepatic artery. A left hemihepatectomy 
was performed in this patient (Fig. 2–4) and lymph nodes from 
the proper hepatic artery area were excised. In the postoperative 
course a short-term bile leak was observed. 
In the second patient, the metastasis to the VI segment 
of the liver (Fig. 5) has occurred 3 years after gastrectomy due 
to cancer. In this case, the resection of the VI segment of the 
liver was performed (Fig. 6) and the postoperative course was 
free from complications.
In turn, in the third patient two metachronous liver meta-
stases (first to IV segment, and the second to VI segment) appe-
ared one year after gastrectomy due to cancer. Liver segment VI 
was removed and left hemihepatectomy was performed. The 
postoperative course was also free of complications.
The fourth patient had a synchronous metastasis to the II and 
III segments of the liver. He underwent simultaneous gastrectomy 
and non-anatomic resection of the II/III segment of the liver. Po-
stoperative treatment proceeded without complications.
Figures 1–4 show metastases of gastric cancer located on 
the border of segments II, III and IV of the liver.
If the tumor lesions are smaller and located more super-
ficially, more limited liver resection can be performed with 
a sufficient oncological margin (Fig. 5–6). 
The scope of liver resection depended on the location 
of the metastatic lesion (Tab. IV). Moreover, all four patients 
received adjuvant chemotherapy.
Two of the operated patients are still alive – one with 
metachronous metastasis (15 months after liver resection) 
and the other with synchronous metastasis (14 months after 
gastrectomy and liver resection). However, the patient with 
liver metastasis and lymph nodes over the liver artery died 
3 months after the operation. The patient with a single me-
tastasis to the VI segment of the liver also died – 9 months 
after the surgery. 
Discussion
Gastric cancer, especially in China, Japan and Korea, is a com-
mon neoplasm. It is less common in European countries and 
the United States, but, which is particularly important, many 
patients are diagnosed with advanced cancer because there 
are no characteristic early symptoms and screening outside 
Japan is not carried out. Gastric cancer often causes metastases 
to many organs and structures at the same time: peritoneum, 
liver, lymph nodes. As result, only a few patients with metastatic 
lesions to the liver can undergo liver resection. 
Not all prognostic factors for patients with metastases of 
gastric cancer into the liver (especially for patients with syn-
Table I . Patients with liver metastases 
Primary lesion Number of patients Percentage
Colorectal cancer 429 patients 87.9%
Eye or skin melanoma 18 patients 3.7%
Kidney cancer 9 patients 1.8%
Ovarian cancer 9 patients 1.8%
Sarcoma (various primary 
locations)
8 patients 1.6%
GIST 6 patients 1.2%
Lung cancer 5 patients 1.0%
Gastric cancer 4 patients 0.8%
Total 488 patients 100%
Table II . Patients with liver metastases only from tumors other than 
colorectal cancer 
Primary lesion Number of patients Percentage
Eye or skin melanoma 18 patients 30.5%
Kidney cancer 9 patients 15.2%
Ovarian cancer 9 patients 15.2%
Sarcoma (various primary 
locations)
8 patients 13.6%
GIST 6 patients 10.2%
Lung cancer 5 patients 8.5%
Gastric cancer 4 patients 6.8%
Total 59 patients 100%
Table III . Types of surgeries in patients with liver metastases 
Surgery type Number of patients Percentage
Minor liver resection* 204 patients 47.9%
Hemihepatectomy 102 patients 23.9%
Thermoablation 86 patients 20.2%
Laparotomy 34 patients 8.0%
Total 426 patients 100%
*According to the international classification – resection of < 2 liver segments
3Figure 1 . Computed tomography of a patient with a gastric cancer 
metastasis on the border of segments II, III and IV of the liver
Figure 2 . Preparation – left hemihepatectomy (the same patient as in 
Fig. 1)
Figure 3 . A cut-through preparation – left hemihepatectomy (the same 
patient as in Fig. 1)
Figure 4 . Condition after left hemihepatectomy (the same patient as in 
Fig. 1)
Figure 5 . Computed tomography of a patient with metastasis from 
gastric cancer to the VI liver segment
Figure 6 . Preparation after resection of a metastasis in segment VI of 
the liver 
4chronous metastases) are known. It is known, however, that 
the prognosis for these patients is bad. 
There are two types of prognostic factors: the first is related 
to the primary tumor and the second to the liver factor. The 
well-known factors, which are associated with the primary 
tumor and influence the survival of patients with gastric can-
cer, include: the depth of gastric wall infiltration by the tumor 
tissue and the coexistence of lymph node metastases [15, 
16]. However, there are publications that question the im-
portance of these prognostic factors in patients with hepatic 
metastases [17].
One of the important prognostic factors for survival of 
patients with metastases to the liver is the number of meta-
stases. In the case of single lesions the 5-year survival rate is as 
much as 55% [15], while at numerous metastases it is 0% [18, 
19]. In several studies, in case of single metastases, the tumor 
size was also taken into account as a prognostic factor [16], 
but this observation was not confirmed by other authors [20].
The 5-year survival of patients with single metastases of 
gastric and colorectal cancer was compared to that of the liver. 
The results were very similar [21]. However, 5-year survival after 
liver resection due to multi-site metastases of gastric cancer is 
much lower than in patients with colorectal cancer metastases 
[22, 23]. It was also analyzed whether synchronous metastases 
to the liver should be considered as a contraindication to the 
resection of this organ. In the authors’ opinion, there are no 
grounds for this [22]. However, we should not overlook another 
publication the authors of which express the opposite opinion. 
It is justified by the findings that patients with synchronous 
metastases of gastric cancer to the liver also have extrahepa-
tic metastases, and the disease itself is very advanced in the 
stomach [24]. 
 The course of recurrent metastases of gastric cancer and 
colorectal cancer to the liver was also compared. It turned 
out that in the case of gastric cancer the recurrence of the 
disease occurred earlier than in colorectal cancer. In addition, 
the majority of patients with recurrent gastric cancer were not 
eligible for repeated surgery. On this basis, the oncological 
aggressiveness of gastric cancer metastases was estimated 
to be much higher than colorectal cancer metastases [25].
An important issue is also performing repeated liver re-
sections in case of recurrence of metastases to this organ. 
To this day, however, there is no clear answer as to whether 
repeated liver resection prolongs the lives of patients with 
gastric cancer [26].
In one publication it was pointed out that the presence of 
a fibrous pseudocapsule around the metastasis is a beneficial 
prognostic factor in metastases of gastric cancer into the liver. 
This should be explained by the fact that it occurs as a defen-
sive reaction of an immunological and inflammatory nature 
against a metastatic lesion. This, in turn, would serve to stop 
further infiltration of the cancer process [26].
Chemotherapy is a separate issue in patients with meta-
stases of gastric cancer into the liver. Chemotherapy – as the 
only form of treatment of patients with liver metastases – gives 
worse results than the surgical treatment combined with sub-
sequent chemotherapy. Adjuvant chemotherapy is considered 
mandatory after metastatic resection [27].
Some publications stress that patients who cannot have 
liver resection with a metastatic lesion of gastric cancer should 
undergo a tumor thermoablation. Such action gives patients 
a chance for longer survival [28, 29].
In 2017, a summary of a review-based work [30] conclu-
ded that liver resection with gastric cancer metastases gives 
a  longer median of patients’ survival compared to palliative 
treatment. However, the authors stated that the final confir-
mation of such a position requires randomized studies.
A comprehensive summary of the knowledge on liver 
resection with metastases from gastric cancer is presented 
in several other publications from recent years [31, 32]. The 
authors emphasize that two types of prognostic factors should 
be taken into account: one concerns the primary tumor and 
the other the metastatic lesion in the liver. Factors related 
to the primary tumor include the stage of the tumor, which 
should not exceed the T2 stage of the tumor. On the other 
hand, the liver factor is connected with the number and size 
Table IV . Patient survival time after liver resection and follow-up time
Time to develop metastasis to 
the liver
Location of the 
metastatic lesion
Surgery type Survival time after liver 
resection
Cause of death
Liver metastasis in 27 years after 
gastrectomy
On the border of 
segments II, III, IVA 
and IVB
Left hemihepatectomy and 
lymphadenectomy
3 months Cancer relapse leading to 
stricture of bile ducts and 
biliary sepsis
Liver metastasis in 3 years after 
gastrectomy
Segment VI Resection of segment VI 9 months Extensive form of cancer 
disease –  including bone 
metastases
Liver metastases in one year 
after gastrectomy
Segments IV and VI Left hemihepatectomy and 
resection of segment VI
The patient lives – 15 
months after liver resection
Synchronous metastasis to the 
liver
Segments II and III Simultaneous gastrectomy 
and excision of segments II 
and III of the liver
The patient lives 
– 14 months after 
simultaneous gastrectomy 
and liver resection
5of metastatic lesions. Patients with single metastases to the 
liver with a diameter of < 4 cm and metachronous metastases 
have the best prognosis. 
A similar meta-analysis was presented in Annals of Surgery 
in 2016 [33]. It confirms that liver resection with single metasta-
ses of gastric cancer in patients without peritoneal spreading 
is a viable option: 1 year – in 68% patients, 2 years – in 31% 
and 5 years – in 27% patients. These results are more favorable 
than after treatment with cytostatic agents only, because in this 
group only 46% of patients experiences one-year survival. The 
same study emphasizes that the success of treatment depends 
on the oncological margin during liver resection, the severity 
of lesions in the lymph nodes and the presence of neoplastic 
lesions in venous blood vessels. In the majority of patients liver 
resections were of a minor nature (< 2 segments). The authors 
of this study also observed that in the Far East the results of 
resection treatment are better than in the West.
In another publication, a Korean group of surgeons eva-
luated the results of resection of metastases of gastric cancer 
into the liver in relation to the primary tumor. They showed 
that patients with type I or II according to pathomorphological 
classification of gastric cancer and intestinal form of gastric 
cancer have better prognosis [34]. Once again, it was pointed 
out that the results of liver resection are influenced by the type 
and degree of advancement of the primary tumor.
Conclusions
Finally, other publications [35, 36] and results obtained by 
our clinic (although they concern a small group of patients, 
as in other single liver surgery centers) indicate that in some 
patients (single metachronous metastasis, no extrahepatic 
lesions, no peritoneal lesions, with subsequent chemotherapy) 
liver resection due to gastric cancer metastases offers a better 
chance of survival than just chemotherapy.
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